Filing Details

Accession Number:
0001209191-17-006406
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-01-31 16:51:53
Reporting Period:
2017-01-31
Filing Date:
2017-01-31
Accepted Time:
2017-01-31 16:51:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1341382 N James Topper C/o Frazier Healthcare Partners
601 Union Street, Suite 3200
Seattle WA 98101
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-01-31 2,228,377 $0.00 2,228,377 No 4 C Indirect see footnote
Common Stock Acquisiton 2017-01-31 733,740 $0.00 733,740 No 4 C Indirect see footnote
Common Stock Acquisiton 2017-01-31 209,095 $0.00 209,095 No 4 C Indirect see footnote
Common Stock Acquisiton 2017-01-31 311,291 $15.00 1,045,031 No 4 P Indirect see footnote
Common Stock Acquisiton 2017-01-31 88,709 $15.00 297,804 No 4 P Indirect see footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect see footnote
No 4 C Indirect see footnote
No 4 C Indirect see footnote
No 4 P Indirect see footnote
No 4 P Indirect see footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2017-01-31 1,428,571 $0.00 1,428,571 $0.00
Common Stock Series C Preferred Stock Disposition 2017-01-31 604,055 $0.00 604,055 $0.00
Common Stock Series C-1 Preferred Stock Disposition 2017-01-31 195,751 $0.00 195,751 $0.00
Common Stock Series D Preferred Stock Disposition 2017-01-31 733,740 $0.00 733,740 $0.00
Common Stock Series D Preferred Stock Disposition 2017-01-31 209,095 $0.00 209,095 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.
  2. Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Ventures. Dr. Topper is a General Partner of Frazier Healthcare. Mr. Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
  3. Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Ventures. Dr. Topper is a General Partner of Frazier Healthcare. Mr. Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
  4. Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Ventures. Dr. Topper is a General Partner of Frazier Healthcare. Mr. Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.